Blood pressure lowering drugs significantly reduced the risk of fatal and nonfatal stroke recurrence in patients with prior stroke or TIA (RR 0.72; 95% CI 0.61 to 0.85).
Meta-Analysis (n=6,752)
Do blood pressure lowering drugs reduce the recurrence of stroke in patients with prior stroke or transient ischemic attack?
Blood pressure lowering therapy significantly reduces the risk of recurrent stroke in patients with a history of stroke or TIA.
Relative Risk: 0.72 (95% CI 0.61–0.85)
BACKGROUND AND PURPOSE: Drug treatment of high blood pressure has been shown to reduce the associated cardiovascular risk. Stroke represents the type of event more strongly linked with high blood pressure, responsible for a high rate of death or invalidity, and with the highest proportion of events that can be avoided by treatment. Hypertensive patients with a history of cerebrovascular accident are at particularly high risk of recurrence. Specific trials of blood pressure lowering drugs in stroke survivors showed inconclusive results in the past. METHODS: We performed a meta-analysis using all available randomized controlled clinical trials assessing the effect of blood pressure lowering drugs on clinical outcomes (recurrence of stroke, coronary events, cause-specific, and overall mortality) in patients with prior stroke or transient ischemic attack. RESULTS: We identified 9 trials, including a total of 6752 patients: 2 trials included 551 hypertensive stroke survivors; 6 trials of hypertensive patients included a small proportion of stroke survivors (536 patients); 1 trial included stroke survivors, whether hypertensive or not (5665 patients). The recurrence of stroke, fatal and nonfatal, was significantly reduced in active groups compared with control groups consistently across the different sources of data (relative risk of 0.72, 95% confidence interval: 0.61 to 0.85). There was no evidence that this intervention induced serious adverse effect. CONCLUSIONS: Blood pressure lowering drug interventions reduced the risk of stroke recurrence in stroke survivors. Available data did not allow to verify whether such benefit depends on initial blood pressure level. More data are needed before considering antihypertensive therapy in normotensive patients at high cerebrovascular risk.
Gueyffier et al. (Mon,) conducted a meta-analysis in prior stroke or transient ischemic attack (n=6,752). Blood pressure lowering drugs vs. control groups was evaluated on recurrence of stroke, fatal and nonfatal (RR 0.72, 95% CI 0.61 to 0.85). Blood pressure lowering drugs significantly reduced the risk of fatal and nonfatal stroke recurrence in patients with prior stroke or TIA (RR 0.72; 95% CI 0.61 to 0.85).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: